Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
Throughout the last 10 years, liver cancer mortality rate in the Russian Federation consistently exceeded the morbidity rate, which is related to the complexity of early diagnostics, absence of effective screening and oncological alertness of allied-profession doctors. In the situation when late dis...
Guardado en:
Autor principal: | L. V. Bolotina |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cb2ff4929a5f4cb3bd687c20f6296f18 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021) -
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Xiaozhun Huang, et al.
Publicado: (2021) -
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression
por: Ai,Xuejun, et al.
Publicado: (2018) -
Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo
por: Ching-Hsuan Wu, et al.
Publicado: (2022) -
First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
por: Shigeo Shimose, et al.
Publicado: (2021)